Inovio Pharmaceuticals has reported positive interim results from a Phase II leukaemia trial of its WT1 DNA vaccine.

The WT1 DNA vaccine, delivered with Inovio’s electroporation delivery system, demonstrated vaccine-specific antibody responses including T cell immune responses in all vaccinated subjects.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Inovio CEO Dr Joseph Kim said the preliminary Phase II data demonstrated the vaccine’s potential to produce T cells and antibodies to treat leukaemia.

"These results follow on our recent scientific breakthrough represented by our human data showing the powerful killing effect of T cells generated by our cervical dysplasia therapeutic vaccine," Kim said.

"The WT1 DNA vaccine, delivered with Inovio’s electroporation delivery system, demonstrated vaccine-specific antibody responses including T cell immune responses in all vaccinated subjects."

According to the preliminary data, the vaccine, which was developed by the University of Southampton, demonstrated a good safety profile and was well-tolerated by the subjects.

See Also:

The Phase II trial will enrol 31 patients in its chronic myelogenous leukaemia (CML) arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

So far, 14 CML patients have been enrolled, while another 13 unvaccinated CML patients were enrolled to serve as a control group.

The trial will enrol the acute myeloid leukaemia (AML) clinical trial arm, with a total target of 37 subjects in each of the vaccinated and control groups.

Open-label, multi-centre Phase II trial is evaluating a DNA vaccine-based immune therapy with molecular responses to BCR-ABL in CML patients and time to disease progression in AML patients are the primary endpoints.

WT1 transcript levels, immune responses to the WT1 antigen, time to progression,overall survival and two-year survival in the AML group will also be monitored in the study.